Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 7/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6000426 | 0.85 | SLC6A4 (0.48) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5502055 | 0.84 | TAAR1 (0.44) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL6000432 | 0.81 | HTR2A (0.32) | TAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL5502917 | 0.80 | TAAR1 (0.45) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL5507294 | 0.76 | SLC6A4 (0.48) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL5497104 | 0.75 | SOS1 (0.38) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL5503523 | 0.75 | TAAR1 (0.43) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL5502216 | 0.75 | SLC6A4 (0.42) | TAAR1ADRA1AHTR2ASLC6A4KCNH2 | |
| SCHEMBL5502595 | 0.75 | TAAR1 (0.47) | SOS1TAAR1ADRA1AHTR2ASLC6A4 | |
| SCHEMBL5496498 | 0.73 | TAAR1 (0.36) | SOS1TAAR1ADRA1AHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SOS1 3837/4885TAAR1 283/4885ADRA1A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.